Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report

Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: A single‐center report

Abstract Background Emicizumab, a bispecific antibody factor VIII mimetic, is approved for prophylaxis in hemophilia, and has different risks and side effects compared to factor VIII products. Objective To better understand the early impact of emicizumab on our patients at the University of Colorado...

Full description

Bibliographic Details
Main Authors: Beth Boulden Warren, Adrian Chan, Marilyn Manco‐Johnson, Brian R. Branchford, Tyler W. Buckner, Genevieve Moyer, Elizabeth Gibson, Dianne Thornhill, Michael Wang, Christopher J Ng
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
bleeding
emicizumab
factor VIII
hemophilia
hemophilia A
Online Access:https://doi.org/10.1002/rth2.12571

Internet

https://doi.org/10.1002/rth2.12571

Similar Items